89 related articles for article (PubMed ID: 12542890)
1. Biorelevant dissolution testing of St John's wort products.
Westerhoff K; Kaunzinger A; Wurglics M; Dressman J; Schubert-Zsilavecz M
J Pharm Pharmacol; 2002 Dec; 54(12):1615-21. PubMed ID: 12542890
[TBL] [Abstract][Full Text] [Related]
2. [Formulation of St. John's wort extract. A medicinal obstacle course].
Schmidt PC
Pharm Unserer Zeit; 2003; 32(3):203-11. PubMed ID: 12784540
[No Abstract] [Full Text] [Related]
3. Comparison of German St. John's wort products according to hyperforin and total hypericin content.
Wurglics M; Westerhoff K; Kaunzinger A; Wilke A; Baumeister A; Dressman J; Schubert-Zsilavecz M
J Am Pharm Assoc (Wash); 2001; 41(4):560-6. PubMed ID: 11486982
[TBL] [Abstract][Full Text] [Related]
4. Batch-to-batch reproducibility of St. John's wort preparations.
Wurglics M; Westerhoff K; Kaunzinger A; Wilke A; Baumeister A; Dressman J; Schubert-Zsilovecz M
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S152-6. PubMed ID: 11518067
[TBL] [Abstract][Full Text] [Related]
5. St. John's wort.
Lawvere S; Mahoney MC
Am Fam Physician; 2005 Dec; 72(11):2249-54. PubMed ID: 16342849
[TBL] [Abstract][Full Text] [Related]
6. Effects of a methanolic extract and a hyperforin-enriched CO2 extract of St. John's Wort (Hypericum perforatum) on intracerebral field potentials in the freely moving rat (Tele-Stereo-EEG).
Dimpfel W; Schober F; Mannel M
Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():30-5. PubMed ID: 9684945
[TBL] [Abstract][Full Text] [Related]
7. [Charge conformity and biopharmaceutic characterization. St. John's Wort extract preparations in comparison].
Wurglics M; Schubert-Zsilavecz M
Pharm Unserer Zeit; 2003; 32(3):236-41. PubMed ID: 12784544
[No Abstract] [Full Text] [Related]
8. Comparison of the synaptosomal uptake inhibition of serotonin by St John's wort products.
Schulte-Löbbert S; Holoubek G; Müller WE; Schubert-Zsilavecz M; Wurglics M
J Pharm Pharmacol; 2004 Jun; 56(6):813-8. PubMed ID: 15231048
[TBL] [Abstract][Full Text] [Related]
9. Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
Nahrstedt A; Butterweck V
J Nat Prod; 2010 May; 73(5):1015-21. PubMed ID: 20408551
[TBL] [Abstract][Full Text] [Related]
10. TESTING PHARMACEUTICAL RELEASE OF ACTIVE SUBSTANCES FROM MEDICINAL PRODUCTS CONTAINING ST. JOHN'S WORT.
Sakowska J; Anyzewska M; Łozak A; Kowalczuk A; Jabłczyńska R
Acta Pol Pharm; 2016; 73(2):395-401. PubMed ID: 27180432
[TBL] [Abstract][Full Text] [Related]
11. Modulation of P-glycoprotein function by St John's wort extract and its major constituents.
Weber CC; Kressmann S; Fricker G; Müller WE
Pharmacopsychiatry; 2004 Nov; 37(6):292-8. PubMed ID: 15551196
[TBL] [Abstract][Full Text] [Related]
12. [Quantitative analysis of active substances in St. John's wort (Hypericum perforatum L.) by the high performance liquid chromatography method].
Kazlauskas S; Bagdonaite E
Medicina (Kaunas); 2004; 40(10):975-81. PubMed ID: 15516821
[TBL] [Abstract][Full Text] [Related]
13. [Hypericin and hyperforin: bioactive components of St. John's Wort (Hypericum perforatum). Their isolation, analysis and study of physiological effect].
Vacek J; Klejdus B; Kubán V
Ceska Slov Farm; 2007 Apr; 56(2):62-6. PubMed ID: 17619301
[TBL] [Abstract][Full Text] [Related]
14. Phytochemical characterization of various St. John's Wort extracts.
Kurth H; Spreemann R
Adv Ther; 1998; 15(2):117-28. PubMed ID: 10180998
[TBL] [Abstract][Full Text] [Related]
15. Analysis and stability of the constituents of artichoke and St. John's wort tinctures by HPLC-DAD and HPLC-MS.
Bilia AR; Bergonzi MC; Mazzi G; Vincieri FF
Drug Dev Ind Pharm; 2002 May; 28(5):609-19. PubMed ID: 12098850
[TBL] [Abstract][Full Text] [Related]
16. Effects of two different extracts of St. John's wort and some of their constituents on cytochrome P450 activities in rat liver microsomes.
Nöldner M; Chatterjee S
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S108-10. PubMed ID: 11518056
[TBL] [Abstract][Full Text] [Related]
17. Determination of total hypericins in St. John's wort and herbal medicinal products.
Anyzewska M; Kowalczuk A; Łozak A; Jabłczyńska R; Fijałek Z
Acta Pol Pharm; 2010; 67(6):586-92. PubMed ID: 21229872
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of β1 -adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside from St John's wort.
Jakobs D; Hage-Hülsmann A; Prenner L; Kolb C; Weiser D; Häberlein H
J Pharm Pharmacol; 2013 Jun; 65(6):907-15. PubMed ID: 23647684
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro.
Capasso R; Borrelli F; Capasso F; Mascolo N; Izzo AA
Urology; 2004 Jul; 64(1):168-72. PubMed ID: 15245964
[TBL] [Abstract][Full Text] [Related]
20. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.
Laakmann G; Schüle C; Baghai T; Kieser M
Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():54-9. PubMed ID: 9684948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
